Clinical Trial

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (carmustine) directly into the artery in the liver to treat liver cancers. Chemotherapy drugs, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. transarterial chemoembolization with carmustine in combination with ethiodized oil and gelatin sponge may help cause the tumors in the liver to shrink or disappear.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-01-25; most recent amendment 2026-05-04.
Status change: Recruiting → Active, Not Recruiting 2025-02-07
Status change: Not Yet Recruiting → Recruiting 2021-10-18
Trial Details
NCT Number NCT04728633
Lead Sponsor Thomas Jefferson University
Conditions Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
Enrollment 28 participants
Start Date 2021-09-27
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-06